Kerstin Nolle Vokinger

List of Publications by Year in Descending Order

27 papers	389 citations	11 h-index	19 g-index
32 ext. papers	673 ext. citations	11.7 avg, IF	5.01 L-index

#	Paper	IF	Citations
27	New EU regulation on health technology assessment of cancer medicines.. *Lancet Oncology, The*, **2022**, 23, e58	21.7	2
26	Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019.. *JAMA Network Open*, **2022**, 5, e226479	10.4	2
25	Kosten-Nutzen-Bewertung von Arzneimitteln **2021**, 57-66		1
24	Hochpreisigkeit bei Onkologika **2021**, 79-92		6
23	Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis. *The Lancet Digital Health*, **2021**, 3, e195-e203	14.4	71
22	Patients\access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe. *Lancet Regional Health - Europe, The*, **2021**, 3, 100050		1
21	Continual learning in medical devices: FDA\s action plan and beyond. *The Lancet Digital Health*, **2021**, 3, e337-e338	14.4	14
20	Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. *Nature Reviews Clinical Oncology*, **2021**,	19.4	2
19	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. *JAMA Oncology*, **2021**, 7, e212026	13.4	14
18	Regulating AI in medicine in the United States and Europe. *Nature Machine Intelligence*, **2021**, 3, 738-739	22.5	3
17	Lost in Anonymization - A Data Anonymization Reference Classification Merging Legal and Technical Considerations. *Journal of Law, Medicine and Ethics*, **2020**, 48, 228-231	1.2	4
16	Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. *Lancet Oncology, The*, **2020**, 21, 664-670	21.7	55
15	Digital health and the COVID-19 epidemic: an assessment framework for apps from an epidemiological and legal perspective. *Swiss Medical Weekly*, **2020**, 150, w20282	3.1	36
14	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. *Journal of Clinical Oncology*, **2020**, 38, 7052-7052	2.2	
13	Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018. *Health Policy*, **2020**, 124, 261-267	3.2	5
12	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. *BMJ, The*, **2020**, 371, m3434	5.9	22
11	Applicability of color-coded computed tomography images in lung volume reduction surgery planning. *Journal of Thoracic Disease*, **2019**, 11, 766-776	2.6	5

List of Publications

10	Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs. *Health Policy*, **2019**, 123, 721-727	3.2	3
9	Evaluating New Rules on Transparency in Cancer Research and Drug Development. *JAMA Oncology*, **2019**, 5, 461-462	13.4	2
8	Pharmacoepidemiology and the Law **2019**, 140-163		
7	Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU. *BMJ Open*, **2019**, 9, e028634	3	12
6	Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine. *JAMA - Journal of the American Medical Association*, **2019**, 322, 2285-2286	27.4	52
5	Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. *JAMA Internal Medicine*, **2019**, 179, 374-380	11.5	14
4	Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning. *European Radiology*, **2019**, 29, 2207-2217	8	35
3	Access to Cancer Precision Medicines in Switzerland: A Comparative Analysis (USA and EU) and Health Policy Implications. *Public Health Genomics*, **2018**, 21, 238-243	1.9	1
2	Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous F-choline PET/MRI for prostate cancer. *EJNMMI Research*, **2018**, 8, 41	3.6	7
1	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. *JCO Oncology Practice*,	2.3	2